Medcount Technologies GmbH, formerly Zatloukal Innovations GmbH, was spun off from the Medical University of Graz in 2021 to bring research findings into practical, industrial applications. Based on a broad range of expertise, the company develops products for pandemic preparedness and medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats.

Medcount Technologies GmbH has a Framework Partnership Agreement (FPA) with the European Defence Fund (EDF) for CBRN medical countermeasures and has been awarded several grants to develop key medicines that are not available in Europe against CBRN threats.

We are developing a biomanufacturing process for industrial-scale, GMP-compliant manufacturing of biologics in plants that have been genetically modified to produce proteins with human-like glycosylation.

In 2026, Zatloukal Innovations GmbH changed it’s name to Medcount Technologies GmbH.

• ACE2 decoy produced in plants neutralizes SARS-CoV2 variants  (Link to Publication)
• Development and testing of rapid diagnostics for biological agents in the field
• Rapid biomanufacturing of medicines in plants against chemical, biological and radio-nuclear agents
• Development and testing of autoinjectors
• Decorporation and decontamination technologies, personal protective equipment (PPE)